Plain-English translation of NCT03787745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
When doctors treat a heart attack with an emergency procedure to restore blood flow, the sudden rush of blood itself can sometimes damage the heart muscle—a problem called reperfusion injury. This trial is testing whether ischemic postconditioning, a technique that briefly pauses and restarts blood flow several times during treatment, can reduce this damage and prevent heart failure and death compared to standard treatment alone.
A previous large trial suggested this treatment might help, but the results weren't clear because some patients also received an additional procedure that complicated the findings. This new trial is designed to get a clearer answer by testing the treatment in patients who don't receive that additional procedure.
You likely qualify if…
You likely don't qualify if…
If you qualify and agree to participate, you will be randomly assigned to receive either the standard heart attack treatment or the standard treatment plus the brief blood flow pauses (ischemic postconditioning). You will go through the emergency heart attack procedure as you normally would, and the study team will monitor your heart function and health outcomes over time to see if the additional technique reduces complications like heart failure or death.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Denmark
Sponsor
Rigshospitalet, Denmark
Enrollment target
~1,800 participants
Started
February 2019
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thomas Engstrøm, DMSci
Rigshospitalet, Denmark
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.